Dear Client: At the end of April, reports surfaced that the US Drug Enforcement Administration (DEA) will reclassify cannabis from a Schedule I to a Schedule III drug [see WSD 04-30-2024]. Shortly after that report, the US Attorney General confirmed the proposal to reclassify cannabis. You’ll recall, as a Schedule III drug, cannabis would be … Continue reading “Implications of Cannabis Rescheduling”
You are unauthorized to view this page.
This Article was originally published on Wine and Spirits Daily
